期刊文献+

二维超声、彩色多普勒超声、肿瘤标志物诊断卵巢肿瘤的价值

原文传递
导出
摘要 目的:分析二维超声、彩色多普勒超声血流显像及血清CA125的准确性,为卵巢肿瘤的鉴别诊断寻求最佳方法。方法:112例卵巢肿瘤患者于术前7d内行二维超声、彩色多普勒超声检查及测定血清CA125。二维超声观察肿块大小,位置,形态、包膜及同时观察有无肝脏、肾脏及腹腔转移,并进一步应用彩色多普勒超声观察肿块周边及内部血流动力学特征,以及血管分布情况,测定收缩期峰值血流速度(A),舒张期血流速度(B),阻力指数RI数值。CA125测定采外周血3ml,用放射免疫测定法,分离血清进行测定。结果:86例卵巢良性肿瘤中12例及26例卵巢恶性肿瘤中22例二维超声显示恶性肿瘤结构特征,14例良性肿瘤和14例恶性肿瘤RI〈0.4,24例良性肿瘤及40例恶性肿瘤CA125测定〉35U/ml,三种方法联合应用共检出良性肿瘤84例,恶性肿瘤28例;病理诊断其中82例为良性肿瘤,恶性肿瘤24例。三者单独应用及联合应用的敏感性分别为84.7%、53.8%、76.9%,92.3%(P〈0.05),特异性分别为86.0%、83.7%、72.1%,95.3%(P〈0.05)。结论:三者检查方法各有优势及不足,尚未发现筛查早期卵巢恶性肿瘤单一特异性方法,三者检查方法联合应用,多参数综合评价可提高卵巢恶性肿瘤的诊断率。
出处 《中国医师杂志》 CAS 2007年第6期829-830,共2页 Journal of Chinese Physician
  • 相关文献

参考文献8

  • 1Young RC,Walton LA ,Ellenbergss, et al. Adjuvant therapy in stage Ⅱ and stage epithelial ovarian eaneen, result of two prospective randomized trial. N Eng I J Med, 1990, 322:1021.
  • 2Prompeler H J, Madjar H, Maruyama R, et al. Classificaton of adnexal tumors by transvaginal Color Doppler. Gynecol Oncol, 1996,61 (3) : 354-363.
  • 3Emoto M, Iwasaki H, Mimura K, et al. Differences in the angiogencsis of benign and malignant ovarian tumors,demonstrated by analyses of Color Doppler ultrasound, immuunohistry and microvessel density. Cancer, 1997,80(5 ) :899-906.
  • 4Kidron D, Gynecol, Bernheim J,Aviram R, et al. Resistance to blood flow in ovarian tumors:correlation between resistance index and histological pattern of vascularization. Ultrasound obsten, 1999,13:425-433.
  • 5Folkman J, Watson K, ingber B, et al. Induction of angiogenesis during the trasition from hyperplasis to neoplasia Ivature, 1989,339:58-61.
  • 6Roman LD, RLI, Stein SM, et al. Pelvic examination tumor marker lever and gray seale and dopier sonography in the prediction of pelvic cancer. Obstet Gynecol, 1997,89(4) :493-500.
  • 7张云霞,李庭芳.卵巢上皮性癌血清CA125、CA72-4、Cu.Zn-SOD测定的临床意义[J].新疆医科大学学报,2005,28(6):557-560. 被引量:3
  • 8滕剑波,王克,万小平.二维超声、彩色多普勒血流分析及CA125对鉴别卵巢良恶性肿瘤的研究[J].中国医学影像技术,2003,19(5):571-573. 被引量:10

二级参考文献10

  • 1Bast RC Jr, Feeneg M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma[J]. J Clin Invest, 1981,68:1331-1335.
  • 2Negishi Y, Iwabuchi H, Sakunaga H, et al. Serum and tissue measurements of CA72-4 in ovarian caner patients[J]. Gynecol Oncol, 1993,48:148-152.
  • 3Fayed ST, Ahmad SM, Kassim SK, et al. The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer[J]. Dis Markers, 1998,14:155-159.
  • 4Bast RC Jr, Klug TL, St John E , et al. A radioimmunoassay using a monoclonal antibody monitor the course of epithelial ovarian cancer[J]. N Engl J Med, 1983,309:883-887.
  • 5Ishikawa M, Yaginuma Y, Hayashi H, et al. Reactivity of a monoclonal antibody to manganese superoxide dismutase with human ovarian carcinoma[J]. Cancer Research, 1990, 50:2538-2543.
  • 6Vergote IB, Bormer OP, Abeler VM, et al. Evaluation of serum CA125 levels in monitoring of ovarian eaneer[J]. Am J Obstet Gyneeol, 1987,157:88-91.
  • 7Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA125[J]. Gynecol Oncol, 1992,46:191-197.
  • 8汤荣光,胡家骆,刘献华.CA_(125)、CEA、AFP、铁蛋白、β_2-微球蛋白联合检测诊断卵巢癌的探讨[J].实用妇产科杂志,1997,13(3):150-151. 被引量:15
  • 9张新,李联昆,王学平,方海棠,董寅媛.血清C_(A125)放免测定对卵巢恶性肿瘤为主的观察[J].实用肿瘤学杂志,1997,11(4):277-279. 被引量:8
  • 10陆鹏荣,丰有吉.血清 CA_(125) 在预测上皮性卵巢癌术后复发中的价值[J].上海医科大学学报,1998,25(2):144-144. 被引量:2

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部